Literature DB >> 18611663

Azithromycin: the first of the tissue-selective azalides.

I M Hoepelman1, M M Schneider.   

Abstract

The azalide azithromycin, which is derived from erythromycin, contains a methyl-substituted nitrogen in the lactone ring. This 15-membered expanded lactone ring results in improved acid stability and oral bioavailability compared with erythromycin. Azithromycin possesses a broad spectrum of activity against Gram-positive and Gram-negative bacteria, including enhanced activity compared with the macrolides against Haemophilus influenzae and Moraxella catarrhalis. In vitro activity of azithromycin against intracellular and clinically atypical pathogens is also good. Azithromycin has a distinct pharmacokinetic profile compared with other antimicrobial agents, the most prominent feature is its high tissue selectivity. Concentrations of azithromycin in respiratory tract, gynaecological tissue and prostate remain above minimum inhibitory concentrations of pathogens for several days, thus making it possible to use a short-course, once-daily dosing regimen. Another feature of azithromycin is that it rapidly penetrates phagocytic cells, with the release of the antibiotics at local sites of infection. Comparative clinical trials have shown that azithromycin given once daily for 3 or 5 days is comparable to comparator drugs given for 7 or 10 days in the treatment of otitis media, sinusitis, pharyngitis, acute bronchitis, acute infectious exacerbations of chronic bronchitis, community-acquired pneumonia and skin and soft tissue infections in adults. Azithromycin given once daily for 3 days has also been shown to be effective in the treatment of respiratory tract and skin and soft tissue infections in children. In addition, some sexually-transmitted diseases are effectively treated by a single 1-g dose of azithromycin; clinical and microbiological responses were comparable to those recorded using doxycycline given twice daily for 7 days. The short-duration, once-daily dosing regimen is well tolerated in adults and children, and there is no evidence of interaction between azithromycin and theophylline, terfenadine, or cimetidine.

Entities:  

Year:  1995        PMID: 18611663     DOI: 10.1016/0924-8579(95)00009-w

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  15 in total

1.  No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Lynn Purkins; Nolan Wood; Parviz Ghahramani; Diane Kleinermans; Gary Layton; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

2.  Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.

Authors:  Songmao Zheng; Peter Matzneller; Markus Zeitlinger; Stephan Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 3.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

5.  Design and formulation technique of a novel drug delivery system for azithromycin and its anti-bacterial activity against Staphylococcus aureus.

Authors:  M Joyce Nirmala; Amitava Mukherjee; N Chandrasekaran
Journal:  AAPS PharmSciTech       Date:  2013-06-26       Impact factor: 3.246

6.  A comparison of in vitro ADME properties and pharmacokinetics of azithromycin and selected 15-membered ring macrolides in rodents.

Authors:  Astrid Milić; Vlatka Bencetić Mihaljević; Jovica Ralić; Ana Bokulić; Danijela Nožinić; Branka Tavčar; Boris Mildner; Vesna Munić; Ivica Malnar; Jasna Padovan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-10-10       Impact factor: 2.441

7.  Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials.

Authors:  Ziyad S Almalki; Jeff Jianfei Guo
Journal:  Am Health Drug Benefits       Date:  2014-09

Review 8.  Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.

Authors:  Berkley E Gryder; Quaovi H Sodji; Adegboyega K Oyelere
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

Review 9.  Strategies to control trachoma.

Authors:  Anu A Mathew; Angus Turner; Hugh R Taylor
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

10.  Fluorescence determination of azithromycin in pharmaceutical formulations by using the synchronous scanning approach after its acid derivatization.

Authors:  Vanessa G K Almeida; Victor S M Braga; Wagner F Pacheco; Ricardo J Cassella
Journal:  J Fluoresc       Date:  2012-08-29       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.